Index DJIA, S&P 500
P/E 28.32
EPS (ttm) 5.58
Insider Own 0.16%
Shs Outstand 2.41B
Perf Week 1.41%
Market Cap 380.49B
Forward P/E 14.37
EPS next Y 10.99
Insider Trans -1.74%
Shs Float 2.40B
Perf Month -1.88%
Income 14.17B
PEG 6.03
EPS next Q 2.63
Inst Own 71.51%
Short Float 0.66%
Perf Quarter 1.17%
Sales 93.02B
P/S 4.09
EPS this Y 7.43%
Inst Trans -0.39%
Short Ratio 2.25
Perf Half Y -0.67%
Book/sh 28.57
P/B 5.53
EPS next Y 3.12%
ROA 7.62%
Short Interest 15.84M
Perf Year 3.04%
Cash/sh 9.52
P/C 16.60
EPS next 5Y 4.70%
ROE 18.57%
52W Range 144.95 - 175.97
Perf YTD 0.78%
Dividend Est. 4.80 (3.04%)
P/FCF 20.85
EPS past 5Y -0.27%
ROI 14.80%
52W High -10.23%
Beta 0.53
Dividend TTM 4.76 (3.01%)
Quick Ratio 0.91
Sales past 5Y 1.31%
Gross Margin 67.94%
52W Low 8.98%
ATR (14) 1.93
Dividend Ex-Date Feb 16, 2024
Current Ratio 1.16
EPS Y/Y TTM -17.52%
Oper. Margin 25.66%
RSI (14) 49.51
Volatility 1.09% 1.22%
Employees 131900
Debt/Eq 0.44
Sales Y/Y TTM -2.10%
Profit Margin 15.23%
Recom 2.24
Target Price 176.38
Option/Short Yes / Yes
LT Debt/Eq 0.39
EPS Q/Q 25.42%
Payout 84.93%
Rel Volume 1.20
Prev Close 155.77
Sales Surprise 1.78%
EPS Surprise 0.39%
Sales Q/Q -9.83%
Earnings Apr 16 BMO
Avg Volume 7.04M
Price 157.96
SMA20 -0.52%
SMA50 -0.55%
SMA200 -0.96%
Trades
Volume 8,459,566
Change 1.41%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$170 → $163
Dec-01-23 Upgrade
UBS
Neutral → Buy
$167 → $180
Oct-05-23 Initiated
RBC Capital Mkts
Outperform
$178
Sep-06-23 Initiated
HSBC Securities
Hold
$175
May-30-23 Resumed
Citigroup
Buy
$185
Mar-29-23 Initiated
UBS
Neutral
$164
Mar-01-23 Initiated
Guggenheim
Neutral
$161
Nov-18-22 Initiated
Credit Suisse
Neutral
$170
Oct-18-22 Initiated
Barclays
Equal Weight
$175
Oct-14-22 Reiterated
BofA Securities
Neutral
$185 → $178
Jun-22-22 Initiated
Daiwa Securities
Outperform
May-23-22 Resumed
SVB Leerink
Outperform
$200
Apr-06-22 Resumed
Morgan Stanley
Equal-Weight
$173
Mar-16-22 Downgrade
Bernstein
Outperform → Mkt Perform
$180 → $183
Mar-02-22 Resumed
BofA Securities
Neutral
$185
Dec-17-21 Initiated
Goldman
Neutral
$161
Dec-15-21 Reiterated
Citigroup
Buy
$192 → $195
Sep-07-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$187
May-28-21 Resumed
Morgan Stanley
Overweight
$187
Apr-28-20 Downgrade
UBS
Buy → Neutral
$163 → $160
Show Previous Ratings
Mar-27-24 03:56PM
03:39PM
03:32PM
06:41AM
Mar-26-24 05:45PM
05:24PM
Loading…
05:24PM
04:24PM
04:15PM
(The Wall Street Journal)
02:33PM
02:30PM
(The Wall Street Journal)
02:23PM
08:02AM
06:18AM
06:07AM
05:15AM
04:56AM
Loading…
04:56AM
01:20AM
Mar-25-24 02:52PM
Mar-24-24 11:04AM
Mar-22-24 05:07AM
04:25AM
Mar-21-24 11:05AM
11:04AM
10:46AM
10:25AM
10:00AM
08:45AM
05:02AM
Mar-20-24 04:59PM
Mar-19-24 10:51AM
08:49AM
Loading…
08:49AM
08:00AM
03:32AM
Mar-18-24 06:09PM
05:45PM
02:04PM
09:00AM
08:00AM
06:55AM
Mar-17-24 08:50AM
02:31AM
Mar-16-24 03:55AM
Mar-15-24 01:02PM
12:53PM
01:15AM
Mar-14-24 10:51AM
10:33AM
09:38AM
01:26AM
Mar-13-24 09:05AM
08:47AM
08:17AM
05:21AM
Mar-12-24 01:20PM
09:28AM
(Pharmaceutical Business Review)
09:15AM
09:09AM
08:20AM
06:53AM
05:39AM
Mar-11-24 05:45PM
04:30PM
03:04PM
05:35AM
Mar-08-24 10:15AM
Mar-07-24 10:03AM
08:33AM
Mar-06-24 09:00AM
03:39AM
Mar-05-24 05:26PM
03:34PM
12:05PM
09:41AM
09:06AM
06:36AM
(Thomson Reuters StreetEvents)
Mar-04-24 08:28PM
05:45PM
11:51AM
06:00AM
Mar-03-24 08:14AM
Mar-02-24 10:42AM
Mar-01-24 03:59PM
02:44PM
Feb-29-24 05:06AM
04:47AM
04:19AM
Feb-28-24 06:08AM
05:49AM
05:44AM
Feb-27-24 05:45PM
Feb-26-24 12:17PM
06:00AM
Feb-24-24 11:22AM
Feb-23-24 10:02AM
05:43AM
Feb-22-24 11:30AM
10:09AM
08:54AM
03:48AM
Feb-21-24 05:45PM
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Broadhurst Vanessa EVP, Global Corp Affairs Mar 13 '24 Sale 162.16 8,891 1,441,765 15,043 Mar 13 04:36 PM JOHNSON & JOHNSON 10% Owner Feb 29 '24 Option Exercise 0.72 3,855 2,792 4,103,430 Mar 06 03:42 PM JOHNSON & JOHNSON 10% Owner Feb 16 '24 Sale 25.81 3,725 96,142 4,099,575 Mar 06 03:42 PM Decker Robert J VP Corporate Controller Feb 13 '24 Option Exercise 0.00 313 0 19,059 Feb 15 04:53 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 13 '24 Option Exercise 0.00 408 0 24,143 Feb 15 04:53 PM Forminard Elizabeth Executive VP, General Counsel Feb 13 '24 Option Exercise 0.00 651 0 8,576 Feb 15 04:53 PM Duato Joaquin CEO and Chairman of the Board Feb 13 '24 Option Exercise 0.00 3,470 0 364,809 Feb 15 04:53 PM Hait William See Remarks Feb 13 '24 Option Exercise 0.00 834 0 39,074 Feb 15 04:53 PM Fasolo Peter Exec VP, Chief HR Officer Feb 13 '24 Option Exercise 0.00 925 0 112,550 Feb 15 04:53 PM Schmid Timothy EVP, WW Chair, MedTech Feb 13 '24 Option Exercise 0.00 499 0 13,290 Feb 15 04:53 PM Swanson James D. EVP, CIO Feb 13 '24 Option Exercise 0.00 447 0 14,765 Feb 15 04:53 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 13 '24 Option Exercise 0.00 1,302 0 155,517 Feb 15 04:53 PM Wolk Joseph J Exec VP, CFO Feb 13 '24 Option Exercise 0.00 1,780 0 69,663 Feb 15 04:53 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 13 '24 Option Exercise 0.00 651 0 82,599 Feb 15 04:53 PM Decker Robert J VP Corporate Controller Feb 12 '24 Option Exercise 0.00 1,912 0 19,269 Feb 14 06:36 PM Duato Joaquin CEO and Chairman of the Board Feb 12 '24 Option Exercise 0.00 36,618 0 377,239 Feb 14 06:36 PM Taubert Jennifer L EVP, WWC. Innovative Medicine Feb 12 '24 Option Exercise 0.00 26,202 0 167,618 Feb 14 06:36 PM Forminard Elizabeth Executive VP, General Counsel Feb 12 '24 Option Exercise 0.00 2,859 0 8,959 Feb 14 06:36 PM Wolk Joseph J Exec VP, CFO Feb 12 '24 Option Exercise 0.00 25,835 0 78,699 Feb 14 06:36 PM Hait William See Remarks Feb 12 '24 Option Exercise 0.00 8,932 0 42,316 Feb 14 06:36 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 12 '24 Option Exercise 0.00 4,701 0 25,081 Feb 14 06:36 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 12 '24 Option Exercise 0.00 13,813 0 89,014 Feb 14 06:36 PM Schmid Timothy EVP, WW Chair, MedTech Feb 12 '24 Option Exercise 0.00 5,736 0 15,678 Feb 14 06:36 PM Swanson James D. EVP, CIO Feb 12 '24 Option Exercise 0.00 5,456 0 16,013 Feb 14 06:36 PM Fasolo Peter Exec VP, Chief HR Officer Feb 12 '24 Option Exercise 0.00 14,960 0 118,644 Feb 14 06:36 PM Duato Joaquin CEO and Chairman of the Board Feb 09 '24 Option Exercise 90.44 130,969 11,844,836 439,283 Feb 13 05:18 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 09 '24 Option Exercise 90.44 59,397 5,371,865 200,813 Feb 12 07:25 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 09 '24 Sale 156.27 59,397 9,281,969 141,416 Feb 12 07:25 PM Taubert Jennifer L EVP, WW Chair, Pharmaceuticals Feb 08 '24 Option Exercise 0.00 3,739 0 143,329 Feb 12 07:25 PM Decker Robert J VP Corporate Controller Feb 08 '24 Option Exercise 0.00 655 0 17,572 Feb 12 07:24 PM Broadhurst Vanessa EVP, Global Corp Affairs Feb 08 '24 Option Exercise 0.00 1,880 0 21,083 Feb 12 07:24 PM Hait William See Remarks Feb 08 '24 Option Exercise 0.00 3,059 0 34,497 Feb 12 07:24 PM Fasolo Peter Exec VP, Chief HR Officer Feb 08 '24 Option Exercise 0.00 2,135 0 104,465 Feb 12 07:24 PM Schmid Timothy EVP, WW Chair, MedTech Feb 08 '24 Option Exercise 0.00 1,964 0 10,943 Feb 12 07:24 PM Swanson James D. See Remarks Feb 08 '24 Option Exercise 0.00 1,868 0 11,111 Feb 12 07:24 PM Forminard Elizabeth Executive VP, General Counsel Feb 08 '24 Option Exercise 0.00 979 0 6,463 Feb 12 07:24 PM Wolk Joseph J Exec VP, CFO Feb 08 '24 Option Exercise 0.00 3,686 0 53,911 Feb 12 07:25 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Feb 08 '24 Option Exercise 0.00 1,971 0 67,905 Feb 12 07:25 PM Duato Joaquin CEO and Chairman of the Board Feb 08 '24 Option Exercise 0.00 5,225 0 310,583 Feb 12 07:25 PM Hait William See Remarks Jul 26 '23 Option Exercise 90.44 14,698 1,329,287 102,445 Jul 27 05:52 PM Hait William See Remarks Jul 26 '23 Sale 172.00 14,698 2,528,056 87,747 Jul 27 05:52 PM Fasolo Peter Exec VP, Chief HR Officer Jul 25 '23 Sale 170.32 20,000 3,406,498 102,696 Jul 27 05:52 PM Wengel Kathryn E EVP, Chief TO and Risk Officer Jun 12 '23 Sale 160.00 12,465 1,994,400 65,934 Jun 14 04:19 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite